Investigating ZYN002 in Children & Adolescents with Fragile X Syndrome
Project Description:
A Randomized, Double-Blind, Placebo-Controlled Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents with Fragile X Syndrome - RECONNECT (Protocol ID: ZYN2-CL-033) PI: Dr Coffey Co-I: Dr Barbouth
Keyword(s):
Developmental Disabilities, Heritable Disorders (excluding sickle cell)
Core Function(s):
Performing Research or Evaluation
Area of Emphasis
Health-Related Activities
Target Audience:
Children/Adolescents with Disabilities/SHCN
Unserved or Under-served Populations:
Disadvantaged Circumstances, Specific Groups
Primary Target Audience Geographic Descriptor:
Not Applicable
COVID-19 Related Data:
N/A